Abstract
ABSTRACT:
 OBJECTIVE: The objective of this study was to determine the frequency of complete and partial remission after 2 courses of hyper CVAD regimen in newly diagnosed patients of acute lymphoblastic leukemia (ALL).MATERIAL AND METHODS: This study was conducted on 100 patients of ALL presenting to the oncology department of Jinnah Hospital, Lahore and fulfilling the inclusion criteria from 01-012016 to 30-12-2016. Patients were undergone treatment with hyper CVAD regimen according to the standard protocol. Complete or partial remission rate was checked after 2 session of hyper CVAD regimen. CT scan (chest and abdomen) was performed for confirmation of extramedullary disease.
 RESULTS: The mean age of study population was 35.68 ± 8.69 years. There were 48% male patients while female patients were 52%. Complete remission was present in 72% patients. Partial remission was present in 24% patients. There was no significant association between complete remission and age (p-value=0.497). No significant association was found between partial remission and age (p-value=0.103). Significant association was found between partial remission and complete remission with gender having p-value=0.001 and 0.01 respectively.
 CONCLUSION: The frequency of complete and partial remission after 2 courses of hyper CVAD regimen in newly diagnosed patients of ALL was 72% and 24% respectively. Effect modifiers have no significant influence except gender.
Highlights
Acute lymphoblastic leukemia (ALL) alludes to a gathering of hematopoietic neoplasms including cells focused on the lymphoid heredity
Complete or partial remission rate was checked after 2 session of hyper CVAD regimen
Complete remission was present in 72% patients while complete remission was not present in 28% patients (p=0.001) in table-I
Summary
Acute lymphoblastic leukemia (ALL) alludes to a gathering of hematopoietic neoplasms including cells focused on the lymphoid heredity. The fuse of BCR-ABL1 tyrosine kinase inhibitor (eg, imatinib, dasatinib) into the treatment regimen has brought about unrivaled remission rates, thereby enabling more patients to continue to FREQUENCY OF REMISSION AFTER TREATMENT (allo-HCT) It is not yet known whether treatment with chemotherapy in addition to a tyrosine kinase inhibitor will give durable long haul abatements and preferable survival over allo-HCT. More than 80 percent of adult patients with Ph+ALL will accomplish a total abatement (CR) with acceptance chemotherapy that joins a tyrosine kinase inhibitor. Patients who get post-induction treatment may expect five-year survival rates of 40 to 60 percent. Post-induction treatment incorporates an about allo-HCT or the continuation of chemotherapy in addition to tyrosine kinase inhibitor. More than 90 percent of adult patients with Ph+ALL will achieve a hematologic finish remission (CR) with acceptance chemotherapy that joins a tyrosine kinase inhibitor (TKI). Patients who get post-induction therapy may expect five-year survival rates of 40 to 60 percent[4]. Before the availability of TKIs, patients with Ph+ALL had a consistently poor anticipation with couple of survivors at five years after treatment with chemotherapy alone . [7,8,9,10,11,12,13,14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of University Medical & Dental College
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
